185 related articles for article (PubMed ID: 33216370)
1. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.
Quintino de Oliveira B; Catto LFB; Santana BAA; Tellechea MF; Scheucher PS; Scheinberg P; Calado RT
Br J Haematol; 2021 Apr; 193(2):410-414. PubMed ID: 33216370
[TBL] [Abstract][Full Text] [Related]
2. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.
Sun H; Tsai Y; Nowak I; Liesveld J; Chen Y
Stem Cell Res; 2012 Sep; 9(2):77-86. PubMed ID: 22683680
[TBL] [Abstract][Full Text] [Related]
3. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.
Townsley DM; Scheinberg P; Winkler T; Desmond R; Dumitriu B; Rios O; Weinstein B; Valdez J; Lotter J; Feng X; Desierto M; Leuva H; Bevans M; Wu C; Larochelle A; Calvo KR; Dunbar CE; Young NS
N Engl J Med; 2017 Apr; 376(16):1540-1550. PubMed ID: 28423296
[TBL] [Abstract][Full Text] [Related]
4. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
Desmond R; Townsley DM; Dumitriu B; Olnes MJ; Scheinberg P; Bevans M; Parikh AR; Broder K; Calvo KR; Wu CO; Young NS; Dunbar CE
Blood; 2014 Mar; 123(12):1818-25. PubMed ID: 24345753
[TBL] [Abstract][Full Text] [Related]
6. Hematologic recovery induced by eltrombopag in Japanese patients with aplastic anemia refractory or intolerant to immunosuppressive therapy.
Yamazaki H; Ohta K; Iida H; Imada K; Obara N; Tokumine Y; Tomiyama Y; Usuki K; Imajo K; Miyamura K; Sasaki O; Fanghong Z; Hattori T; Tajima T; Matsuda A; Nakao S
Int J Hematol; 2019 Aug; 110(2):187-196. PubMed ID: 31183813
[TBL] [Abstract][Full Text] [Related]
7. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Erickson-Miller CL; Delorme E; Tian SS; Hopson CB; Landis AJ; Valoret EI; Sellers TS; Rosen J; Miller SG; Luengo JI; Duffy KJ; Jenkins JM
Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag for the treatment of aplastic anemia: current perspectives.
Lum SH; Grainger JD
Drug Des Devel Ther; 2016; 10():2833-2843. PubMed ID: 27695288
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag: a review of its use in patients with severe aplastic anaemia.
McCormack PL
Drugs; 2015 Apr; 75(5):525-31. PubMed ID: 25700916
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia.
Cheng H; Wang X; Zhou D; Cao J; Larochelle A; Xu KL
Ann Hematol; 2019 Aug; 98(8):2009-2011. PubMed ID: 30891613
[No Abstract] [Full Text] [Related]
11. [Recent issues and prospects of the treatment of aplastic anemia].
Nakao S
Rinsho Ketsueki; 2014 Jan; 55(1):5-11. PubMed ID: 24492031
[No Abstract] [Full Text] [Related]
12. Longitudinal evaluation of eltrombopag in paediatric acquired severe aplastic anaemia.
Filippidou M; Avgerinou G; Tsipou H; Tourkantoni N; Katsibardi K; Vlachou A; Roka K; Solomou E; Kattamis A
Br J Haematol; 2020 Aug; 190(3):e157-e159. PubMed ID: 32529633
[No Abstract] [Full Text] [Related]
13. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Fattizzo B; Levati G; Cassin R; Barcellini W
Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Olnes MJ; Scheinberg P; Calvo KR; Desmond R; Tang Y; Dumitriu B; Parikh AR; Soto S; Biancotto A; Feng X; Lozier J; Wu CO; Young NS; Dunbar CE
N Engl J Med; 2012 Jul; 367(1):11-9. PubMed ID: 22762314
[TBL] [Abstract][Full Text] [Related]
15. Deficit of circulating CD19
Zaimoku Y; Patel BA; Kajigaya S; Feng X; Alemu L; Quinones Raffo D; Groarke EM; Young NS
Br J Haematol; 2020 Aug; 190(4):610-617. PubMed ID: 32311088
[TBL] [Abstract][Full Text] [Related]
16. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Blood Adv; 2018 Nov; 2(21):3054-3062. PubMed ID: 30425070
[TBL] [Abstract][Full Text] [Related]
17. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
Di Buduo CA; Laurent PA; Zaninetti C; Lordier L; Soprano PM; Ntai A; Barozzi S; La Spada A; Biunno I; Raslova H; Bussel JB; Kaplan DL; Balduini CL; Pecci A; Balduini A
Elife; 2021 Jun; 10():. PubMed ID: 34059198
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag for treatment of thrombocytopenia-associated disorders.
Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
[TBL] [Abstract][Full Text] [Related]
19. Upfront eltrombopag monotherapy induces stable hematologic remission in pediatric patients with nonsevere idiopathic aplastic anemia.
Geng W; Kearney S; Nelson S
Pediatr Blood Cancer; 2018 Oct; 65(10):e27290. PubMed ID: 29932285
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
